Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bipolar Disorder | 227 | 2024 | 5092 | 19.280 |
Why?
|
Antidepressive Agents | 133 | 2023 | 2897 | 8.340 |
Why?
|
Depressive Disorder, Major | 173 | 2024 | 4761 | 7.370 |
Why?
|
Antimanic Agents | 39 | 2023 | 520 | 6.520 |
Why?
|
Antipsychotic Agents | 56 | 2023 | 3067 | 6.180 |
Why?
|
Lithium | 33 | 2023 | 596 | 5.310 |
Why?
|
Lithium Compounds | 25 | 2023 | 223 | 4.680 |
Why?
|
Depressive Disorder | 113 | 2024 | 3728 | 4.570 |
Why?
|
Fluoxetine | 56 | 2012 | 733 | 2.850 |
Why?
|
Psychiatric Status Rating Scales | 141 | 2022 | 6019 | 2.710 |
Why?
|
Psychotherapy | 35 | 2023 | 1647 | 2.580 |
Why?
|
Suicidal Ideation | 18 | 2024 | 1447 | 2.340 |
Why?
|
Antidepressive Agents, Second-Generation | 37 | 2013 | 489 | 2.250 |
Why?
|
Affect | 29 | 2022 | 1486 | 2.190 |
Why?
|
Comparative Effectiveness Research | 13 | 2018 | 709 | 2.170 |
Why?
|
Depression | 51 | 2024 | 8124 | 2.070 |
Why?
|
Psychotropic Drugs | 20 | 2023 | 888 | 1.970 |
Why?
|
Anticonvulsants | 17 | 2023 | 1906 | 1.850 |
Why?
|
Mood Disorders | 19 | 2022 | 1127 | 1.840 |
Why?
|
Suicide | 24 | 2020 | 1601 | 1.750 |
Why?
|
Citalopram | 32 | 2013 | 402 | 1.720 |
Why?
|
Anxiety Disorders | 33 | 2021 | 2720 | 1.670 |
Why?
|
Psychiatry | 20 | 2022 | 1693 | 1.650 |
Why?
|
Treatment Outcome | 189 | 2024 | 64680 | 1.490 |
Why?
|
Suicide, Attempted | 28 | 2024 | 1402 | 1.470 |
Why?
|
Antidepressive Agents, Tricyclic | 21 | 2010 | 432 | 1.400 |
Why?
|
Humans | 559 | 2024 | 761504 | 1.320 |
Why?
|
Adult | 348 | 2024 | 221177 | 1.300 |
Why?
|
Drug Therapy, Combination | 63 | 2022 | 6310 | 1.230 |
Why?
|
Nortriptyline | 8 | 2006 | 79 | 1.210 |
Why?
|
Comorbidity | 75 | 2022 | 10508 | 1.210 |
Why?
|
Drug Resistance | 32 | 2011 | 1596 | 1.100 |
Why?
|
Ambulatory Care | 47 | 2020 | 2775 | 1.080 |
Why?
|
Lithium Carbonate | 10 | 2013 | 179 | 1.080 |
Why?
|
Mental Disorders | 20 | 2022 | 6845 | 1.080 |
Why?
|
Personality Inventory | 42 | 2015 | 1019 | 1.060 |
Why?
|
Randomized Controlled Trials as Topic | 29 | 2022 | 10209 | 1.040 |
Why?
|
Severity of Illness Index | 76 | 2020 | 15842 | 1.040 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 33 | 2022 | 1988 | 1.000 |
Why?
|
Male | 341 | 2024 | 360804 | 0.980 |
Why?
|
Female | 358 | 2024 | 392644 | 0.970 |
Why?
|
Psychotic Disorders | 12 | 2020 | 3223 | 0.960 |
Why?
|
Middle Aged | 252 | 2024 | 220895 | 0.900 |
Why?
|
Exercise Therapy | 4 | 2019 | 929 | 0.860 |
Why?
|
Bupropion | 17 | 2013 | 304 | 0.850 |
Why?
|
Psychotherapy, Group | 3 | 2022 | 412 | 0.850 |
Why?
|
Tremor | 2 | 2014 | 191 | 0.830 |
Why?
|
Neurology | 5 | 2010 | 780 | 0.820 |
Why?
|
Outpatients | 20 | 2023 | 1597 | 0.810 |
Why?
|
Sertraline | 12 | 2023 | 209 | 0.790 |
Why?
|
Psychometrics | 24 | 2022 | 3065 | 0.790 |
Why?
|
Conflict of Interest | 4 | 2014 | 554 | 0.780 |
Why?
|
Affective Symptoms | 5 | 2024 | 417 | 0.780 |
Why?
|
Excitatory Amino Acid Antagonists | 3 | 2019 | 448 | 0.780 |
Why?
|
Mianserin | 11 | 2012 | 51 | 0.780 |
Why?
|
Patient Acceptance of Health Care | 8 | 2021 | 3205 | 0.770 |
Why?
|
Patient Dropouts | 14 | 2011 | 412 | 0.770 |
Why?
|
Apathy | 3 | 2022 | 107 | 0.770 |
Why?
|
Self Report | 14 | 2022 | 3724 | 0.760 |
Why?
|
Ketamine | 4 | 2022 | 519 | 0.740 |
Why?
|
Medication Adherence | 7 | 2019 | 2176 | 0.740 |
Why?
|
Cyclohexanols | 16 | 2013 | 126 | 0.730 |
Why?
|
Exercise | 8 | 2022 | 5890 | 0.710 |
Why?
|
Research Design | 26 | 2019 | 6180 | 0.700 |
Why?
|
Crisis Intervention | 1 | 2021 | 109 | 0.690 |
Why?
|
Anxiety | 14 | 2022 | 4573 | 0.690 |
Why?
|
Young Adult | 69 | 2024 | 59243 | 0.680 |
Why?
|
Double-Blind Method | 54 | 2023 | 12341 | 0.680 |
Why?
|
Adolescent | 125 | 2024 | 88319 | 0.670 |
Why?
|
Dibenzothiazepines | 4 | 2014 | 102 | 0.650 |
Why?
|
Quality of Life | 28 | 2023 | 13367 | 0.640 |
Why?
|
Leukocyte Count | 3 | 2019 | 1596 | 0.640 |
Why?
|
Clinical Trials as Topic | 21 | 2017 | 8002 | 0.630 |
Why?
|
Medical Waste Disposal | 1 | 2018 | 14 | 0.610 |
Why?
|
Peroxisome Proliferator-Activated Receptors | 1 | 2018 | 61 | 0.590 |
Why?
|
Polypharmacy | 2 | 2023 | 306 | 0.590 |
Why?
|
Health Communication | 1 | 2020 | 213 | 0.580 |
Why?
|
Folic Acid | 10 | 2013 | 1323 | 0.560 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 11 | 2021 | 3708 | 0.560 |
Why?
|
Cardiovascular Diseases | 12 | 2023 | 15500 | 0.540 |
Why?
|
Placebo Effect | 4 | 2015 | 518 | 0.540 |
Why?
|
Tetrahydrofolates | 1 | 2016 | 58 | 0.540 |
Why?
|
Combined Modality Therapy | 28 | 2023 | 8529 | 0.530 |
Why?
|
Hypericum | 6 | 2013 | 58 | 0.530 |
Why?
|
Drug Administration Schedule | 32 | 2015 | 4853 | 0.530 |
Why?
|
Buspirone | 5 | 2012 | 81 | 0.520 |
Why?
|
Substance-Related Disorders | 22 | 2023 | 4420 | 0.490 |
Why?
|
Immune System | 2 | 2017 | 796 | 0.490 |
Why?
|
Age of Onset | 28 | 2015 | 3305 | 0.490 |
Why?
|
Personality Disorders | 10 | 2009 | 722 | 0.490 |
Why?
|
Remission Induction | 15 | 2017 | 2396 | 0.490 |
Why?
|
Lithium Chloride | 2 | 2013 | 82 | 0.480 |
Why?
|
Mitochondrial Diseases | 1 | 2018 | 343 | 0.460 |
Why?
|
Psychological Tests | 2 | 2015 | 640 | 0.460 |
Why?
|
Secondary Prevention | 14 | 2019 | 1475 | 0.460 |
Why?
|
Clinical Protocols | 9 | 2017 | 1440 | 0.450 |
Why?
|
Water Pollutants, Chemical | 1 | 2018 | 359 | 0.450 |
Why?
|
Valproic Acid | 7 | 2023 | 443 | 0.440 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2017 | 370 | 0.440 |
Why?
|
Recurrence | 28 | 2011 | 8465 | 0.440 |
Why?
|
Eicosapentaenoic Acid | 6 | 2022 | 561 | 0.440 |
Why?
|
Behavior Therapy | 2 | 2017 | 879 | 0.430 |
Why?
|
Aged | 121 | 2024 | 169289 | 0.430 |
Why?
|
Somatoform Disorders | 8 | 2006 | 423 | 0.430 |
Why?
|
Patient Identification Systems | 1 | 2013 | 75 | 0.430 |
Why?
|
Executive Function | 7 | 2023 | 1389 | 0.430 |
Why?
|
Dose-Response Relationship, Drug | 33 | 2020 | 10766 | 0.430 |
Why?
|
Logistic Models | 21 | 2019 | 13255 | 0.420 |
Why?
|
Prescription Drugs | 2 | 2018 | 631 | 0.420 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 3 | 2009 | 324 | 0.420 |
Why?
|
Triiodothyronine | 6 | 2014 | 493 | 0.420 |
Why?
|
Acetaminophen | 1 | 2017 | 554 | 0.410 |
Why?
|
Inositol | 4 | 2012 | 215 | 0.410 |
Why?
|
Child Behavior Disorders | 3 | 2006 | 804 | 0.410 |
Why?
|
Cost of Illness | 10 | 2021 | 1936 | 0.410 |
Why?
|
Patient-Centered Care | 3 | 2021 | 1421 | 0.410 |
Why?
|
Diet, Mediterranean | 1 | 2019 | 740 | 0.400 |
Why?
|
Anger | 9 | 2007 | 406 | 0.400 |
Why?
|
Phytotherapy | 7 | 2014 | 296 | 0.400 |
Why?
|
Evidence-Based Medicine | 7 | 2019 | 3688 | 0.390 |
Why?
|
Physician-Patient Relations | 5 | 2020 | 3249 | 0.390 |
Why?
|
Disease Progression | 9 | 2016 | 13506 | 0.380 |
Why?
|
Vitamin B 12 | 8 | 2013 | 524 | 0.380 |
Why?
|
bcl-X Protein | 1 | 2013 | 410 | 0.380 |
Why?
|
Environmental Monitoring | 1 | 2018 | 1460 | 0.370 |
Why?
|
Meditation | 2 | 2011 | 251 | 0.370 |
Why?
|
Stress Disorders, Post-Traumatic | 6 | 2023 | 4575 | 0.370 |
Why?
|
Veterans | 4 | 2023 | 2647 | 0.360 |
Why?
|
Diabetes Mellitus | 5 | 2023 | 5840 | 0.360 |
Why?
|
Decision Making | 5 | 2016 | 3929 | 0.360 |
Why?
|
Drug Therapy | 3 | 2011 | 503 | 0.360 |
Why?
|
Prevalence | 29 | 2024 | 15732 | 0.350 |
Why?
|
United States | 44 | 2024 | 72334 | 0.350 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2010 | 36 | 0.350 |
Why?
|
Drug Industry | 2 | 2008 | 788 | 0.350 |
Why?
|
Electroconvulsive Therapy | 5 | 2022 | 500 | 0.350 |
Why?
|
Counseling | 2 | 2019 | 1547 | 0.350 |
Why?
|
Drugs, Generic | 2 | 2016 | 448 | 0.340 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2019 | 276 | 0.340 |
Why?
|
Patient Participation | 2 | 2018 | 1444 | 0.340 |
Why?
|
Mind-Body Relations, Metaphysical | 1 | 2009 | 36 | 0.340 |
Why?
|
Central Nervous System Agents | 1 | 2010 | 75 | 0.340 |
Why?
|
Cholinesterase Inhibitors | 2 | 2009 | 242 | 0.340 |
Why?
|
Leukocytes | 1 | 2017 | 2026 | 0.330 |
Why?
|
Smoking | 5 | 2014 | 9053 | 0.330 |
Why?
|
Child, Orphaned | 1 | 2010 | 55 | 0.330 |
Why?
|
Risperidone | 2 | 2016 | 381 | 0.330 |
Why?
|
Irritable Mood | 8 | 2017 | 194 | 0.330 |
Why?
|
Follow-Up Studies | 40 | 2019 | 39106 | 0.320 |
Why?
|
Allostasis | 1 | 2009 | 72 | 0.320 |
Why?
|
Triazines | 2 | 2013 | 311 | 0.320 |
Why?
|
Child of Impaired Parents | 4 | 2015 | 460 | 0.320 |
Why?
|
Galantamine | 1 | 2009 | 33 | 0.320 |
Why?
|
Pilot Projects | 16 | 2023 | 8631 | 0.320 |
Why?
|
Propaganda | 1 | 2008 | 7 | 0.310 |
Why?
|
Neuropsychology | 1 | 2009 | 107 | 0.310 |
Why?
|
Journalism, Medical | 1 | 2009 | 73 | 0.310 |
Why?
|
Neurodegenerative Diseases | 1 | 2018 | 1087 | 0.310 |
Why?
|
Drug Monitoring | 5 | 2019 | 962 | 0.310 |
Why?
|
Memory | 2 | 2017 | 2188 | 0.310 |
Why?
|
Trazodone | 4 | 2002 | 68 | 0.310 |
Why?
|
Health Surveys | 8 | 2024 | 4061 | 0.310 |
Why?
|
Benzodiazepines | 5 | 2015 | 1132 | 0.310 |
Why?
|
Sleep Initiation and Maintenance Disorders | 9 | 2014 | 1081 | 0.300 |
Why?
|
Cognition | 8 | 2023 | 6990 | 0.300 |
Why?
|
Behavioral Symptoms | 1 | 2010 | 186 | 0.300 |
Why?
|
Single-Blind Method | 10 | 2013 | 1572 | 0.300 |
Why?
|
Sleep | 3 | 2021 | 4768 | 0.300 |
Why?
|
Melatonin | 2 | 2012 | 669 | 0.300 |
Why?
|
Life Style | 1 | 2019 | 3917 | 0.300 |
Why?
|
Prospective Studies | 43 | 2022 | 54425 | 0.300 |
Why?
|
Risk Factors | 44 | 2021 | 74206 | 0.290 |
Why?
|
Homocysteine | 7 | 2012 | 638 | 0.290 |
Why?
|
Phobic Disorders | 6 | 2021 | 439 | 0.290 |
Why?
|
Feeding Behavior | 3 | 2018 | 3188 | 0.280 |
Why?
|
Drug Discovery | 1 | 2015 | 1051 | 0.280 |
Why?
|
Alcohol-Related Disorders | 2 | 2022 | 238 | 0.280 |
Why?
|
Long-Term Care | 8 | 2012 | 633 | 0.280 |
Why?
|
Panic Disorder | 6 | 2006 | 613 | 0.280 |
Why?
|
Neurogenesis | 2 | 2012 | 863 | 0.280 |
Why?
|
Placebos | 13 | 2015 | 1667 | 0.280 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 2273 | 0.280 |
Why?
|
Longitudinal Studies | 31 | 2023 | 14605 | 0.280 |
Why?
|
Social Adjustment | 7 | 2011 | 632 | 0.270 |
Why?
|
Social Support | 3 | 2015 | 2171 | 0.270 |
Why?
|
Biomedical Research | 2 | 2014 | 3429 | 0.270 |
Why?
|
Brain-Derived Neurotrophic Factor | 3 | 2017 | 602 | 0.260 |
Why?
|
National Institute of Mental Health (U.S.) | 5 | 2011 | 107 | 0.260 |
Why?
|
Risk Assessment | 7 | 2020 | 23995 | 0.260 |
Why?
|
Cross-Sectional Studies | 23 | 2023 | 26125 | 0.250 |
Why?
|
Brain | 13 | 2023 | 27112 | 0.250 |
Why?
|
Social Behavior | 3 | 2010 | 1135 | 0.250 |
Why?
|
Transcranial Magnetic Stimulation | 3 | 2019 | 1472 | 0.250 |
Why?
|
Denmark | 6 | 2024 | 771 | 0.250 |
Why?
|
Sex Factors | 16 | 2020 | 10552 | 0.240 |
Why?
|
Imipramine | 2 | 2002 | 98 | 0.240 |
Why?
|
Financial Support | 1 | 2005 | 117 | 0.240 |
Why?
|
Tachyphylaxis | 2 | 2018 | 54 | 0.240 |
Why?
|
Neuropsychological Tests | 8 | 2024 | 7045 | 0.240 |
Why?
|
Vagus Nerve Stimulation | 1 | 2008 | 227 | 0.240 |
Why?
|
Prefrontal Cortex | 5 | 2022 | 2219 | 0.240 |
Why?
|
Models, Biological | 2 | 2019 | 9469 | 0.240 |
Why?
|
Choline | 5 | 2012 | 515 | 0.230 |
Why?
|
Neurosciences | 1 | 2009 | 367 | 0.230 |
Why?
|
Treatment Failure | 8 | 2014 | 2645 | 0.230 |
Why?
|
Nutrition Therapy | 2 | 2019 | 102 | 0.230 |
Why?
|
Editorial Policies | 1 | 2009 | 458 | 0.230 |
Why?
|
Verbal Learning | 3 | 2017 | 463 | 0.230 |
Why?
|
Mitochondria | 2 | 2021 | 3624 | 0.230 |
Why?
|
Docosahexaenoic Acids | 4 | 2022 | 908 | 0.230 |
Why?
|
Cognition Disorders | 6 | 2014 | 3979 | 0.230 |
Why?
|
Prognosis | 21 | 2019 | 29625 | 0.230 |
Why?
|
Uncertainty | 1 | 2009 | 754 | 0.230 |
Why?
|
Mothers | 2 | 2014 | 2198 | 0.220 |
Why?
|
Guidelines as Topic | 1 | 2010 | 1386 | 0.220 |
Why?
|
Parathyroid Diseases | 1 | 2023 | 46 | 0.220 |
Why?
|
Epidemiology | 2 | 2004 | 279 | 0.220 |
Why?
|
Cohort Studies | 28 | 2024 | 41487 | 0.220 |
Why?
|
Environment | 1 | 2009 | 1123 | 0.220 |
Why?
|
Practice Guidelines as Topic | 9 | 2021 | 7390 | 0.210 |
Why?
|
Paroxetine | 5 | 2010 | 182 | 0.210 |
Why?
|
Plant Extracts | 4 | 2011 | 498 | 0.210 |
Why?
|
Obsessive-Compulsive Disorder | 8 | 2013 | 1491 | 0.210 |
Why?
|
Dysthymic Disorder | 4 | 2014 | 75 | 0.210 |
Why?
|
Personal Satisfaction | 4 | 2019 | 644 | 0.210 |
Why?
|
Gyrus Cinguli | 7 | 2003 | 1115 | 0.210 |
Why?
|
Periodicals as Topic | 3 | 2009 | 1463 | 0.210 |
Why?
|
Reproducibility of Results | 14 | 2022 | 20098 | 0.210 |
Why?
|
Alprazolam | 1 | 2002 | 102 | 0.210 |
Why?
|
Chronic Disease | 18 | 2020 | 9318 | 0.200 |
Why?
|
Patient Care Management | 1 | 2006 | 302 | 0.200 |
Why?
|
Thiophenes | 1 | 2007 | 569 | 0.200 |
Why?
|
Feasibility Studies | 9 | 2023 | 5247 | 0.200 |
Why?
|
Attitude | 2 | 2015 | 775 | 0.200 |
Why?
|
Piperazines | 4 | 2008 | 2523 | 0.200 |
Why?
|
Dietary Supplements | 3 | 2022 | 3415 | 0.200 |
Why?
|
Plants, Medicinal | 2 | 1999 | 165 | 0.200 |
Why?
|
Implosive Therapy | 1 | 2023 | 125 | 0.200 |
Why?
|
Stress, Psychological | 5 | 2009 | 4481 | 0.200 |
Why?
|
Quinolones | 1 | 2005 | 378 | 0.200 |
Why?
|
Oxidative Stress | 3 | 2021 | 3113 | 0.200 |
Why?
|
Cooperative Behavior | 3 | 2019 | 1505 | 0.190 |
Why?
|
Fatty Acids, Omega-3 | 3 | 2022 | 1390 | 0.190 |
Why?
|
Choice Behavior | 3 | 2017 | 824 | 0.190 |
Why?
|
Drug Substitution | 3 | 2013 | 290 | 0.190 |
Why?
|
Statistics as Topic | 6 | 2014 | 2358 | 0.190 |
Why?
|
Family Health | 1 | 2006 | 1257 | 0.190 |
Why?
|
Normal Distribution | 1 | 2021 | 272 | 0.190 |
Why?
|
History, 20th Century | 5 | 2009 | 2767 | 0.190 |
Why?
|
Meta-Analysis as Topic | 4 | 2021 | 1380 | 0.190 |
Why?
|
Risk Management | 1 | 2004 | 558 | 0.180 |
Why?
|
Histamine H2 Antagonists | 1 | 2022 | 166 | 0.180 |
Why?
|
Adult Survivors of Child Abuse | 1 | 2024 | 294 | 0.180 |
Why?
|
Tranylcypromine | 4 | 2006 | 30 | 0.180 |
Why?
|
Health Care Reform | 1 | 2010 | 1247 | 0.180 |
Why?
|
Drug Approval | 2 | 2022 | 814 | 0.180 |
Why?
|
Hostility | 3 | 2006 | 183 | 0.180 |
Why?
|
Inappropriate Prescribing | 1 | 2023 | 211 | 0.180 |
Why?
|
Multicenter Studies as Topic | 5 | 2011 | 1702 | 0.170 |
Why?
|
Desipramine | 7 | 2004 | 182 | 0.170 |
Why?
|
Age Factors | 18 | 2020 | 18395 | 0.170 |
Why?
|
Cholesterol | 3 | 2004 | 2904 | 0.170 |
Why?
|
Brain Mapping | 9 | 2023 | 6630 | 0.170 |
Why?
|
Medicare Part D | 2 | 2016 | 355 | 0.170 |
Why?
|
Interpersonal Relations | 3 | 2008 | 1436 | 0.170 |
Why?
|
Monoamine Oxidase Inhibitors | 5 | 2002 | 156 | 0.170 |
Why?
|
Delayed-Action Preparations | 11 | 2013 | 962 | 0.170 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2021 | 3245 | 0.170 |
Why?
|
Anti-Inflammatory Agents | 2 | 2019 | 1809 | 0.170 |
Why?
|
Propylamines | 3 | 2009 | 161 | 0.170 |
Why?
|
Primary Health Care | 10 | 2022 | 4686 | 0.170 |
Why?
|
Ankyrins | 1 | 2019 | 123 | 0.160 |
Why?
|
Mental Health | 6 | 2023 | 3250 | 0.160 |
Why?
|
Homocystinuria | 1 | 2019 | 64 | 0.160 |
Why?
|
Adrenergic Uptake Inhibitors | 3 | 2009 | 186 | 0.160 |
Why?
|
Decision Support Techniques | 2 | 2011 | 1998 | 0.160 |
Why?
|
Appetite | 4 | 2010 | 247 | 0.160 |
Why?
|
Tetrabenazine | 1 | 2018 | 18 | 0.160 |
Why?
|
Magnetic Resonance Imaging | 20 | 2023 | 36426 | 0.160 |
Why?
|
Risk | 6 | 2017 | 9610 | 0.160 |
Why?
|
Disability Evaluation | 4 | 2016 | 1835 | 0.160 |
Why?
|
Hyperlipidemias | 2 | 2014 | 771 | 0.160 |
Why?
|
History, 21st Century | 3 | 2009 | 1567 | 0.160 |
Why?
|
Sick Role | 4 | 2006 | 229 | 0.160 |
Why?
|
Convulsive Therapy | 1 | 1998 | 3 | 0.160 |
Why?
|
Analysis of Variance | 12 | 2014 | 6228 | 0.160 |
Why?
|
Perylene | 1 | 1998 | 22 | 0.150 |
Why?
|
Muscle Spasticity | 1 | 2019 | 156 | 0.150 |
Why?
|
Xanthenes | 1 | 1998 | 72 | 0.150 |
Why?
|
Probability | 7 | 2013 | 2477 | 0.150 |
Why?
|
Forecasting | 3 | 2016 | 2928 | 0.150 |
Why?
|
Demography | 9 | 2013 | 1648 | 0.150 |
Why?
|
Deductibles and Coinsurance | 1 | 2020 | 316 | 0.150 |
Why?
|
Financing, Personal | 1 | 2020 | 309 | 0.150 |
Why?
|
Education, Pharmacy | 1 | 2018 | 38 | 0.150 |
Why?
|
Calcium Channels, L-Type | 1 | 2019 | 242 | 0.150 |
Why?
|
Thyrotropin | 3 | 2023 | 834 | 0.150 |
Why?
|
Self-Help Groups | 1 | 2019 | 192 | 0.150 |
Why?
|
Quercetin | 1 | 1998 | 97 | 0.150 |
Why?
|
Emotions | 6 | 2021 | 2739 | 0.150 |
Why?
|
Personality | 3 | 2022 | 554 | 0.150 |
Why?
|
Empirical Research | 2 | 2016 | 120 | 0.140 |
Why?
|
Pharmacogenetics | 2 | 2012 | 675 | 0.140 |
Why?
|
CLOCK Proteins | 1 | 2017 | 86 | 0.140 |
Why?
|
Vitamin B Complex | 2 | 2012 | 299 | 0.140 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 3 | 2015 | 306 | 0.140 |
Why?
|
Motivation | 2 | 2014 | 2006 | 0.140 |
Why?
|
Attitude to Health | 4 | 2015 | 2025 | 0.140 |
Why?
|
Valine | 1 | 2018 | 408 | 0.140 |
Why?
|
Community-Institutional Relations | 1 | 2018 | 206 | 0.140 |
Why?
|
Dopamine Agents | 1 | 1998 | 189 | 0.140 |
Why?
|
Problem Solving | 1 | 1999 | 441 | 0.140 |
Why?
|
Terminology as Topic | 3 | 2001 | 1530 | 0.140 |
Why?
|
Consensus | 4 | 2022 | 3123 | 0.140 |
Why?
|
Binge-Eating Disorder | 1 | 2018 | 147 | 0.140 |
Why?
|
Minocycline | 1 | 2018 | 169 | 0.140 |
Why?
|
Internet | 3 | 2022 | 3092 | 0.140 |
Why?
|
Water Supply | 1 | 2018 | 204 | 0.140 |
Why?
|
Parietal Lobe | 2 | 2018 | 852 | 0.130 |
Why?
|
Diagnosis, Differential | 10 | 2010 | 12974 | 0.130 |
Why?
|
Controlled Clinical Trials as Topic | 2 | 2011 | 186 | 0.130 |
Why?
|
Patient Education as Topic | 3 | 2018 | 2319 | 0.130 |
Why?
|
Clozapine | 1 | 2020 | 504 | 0.130 |
Why?
|
Patient Selection | 4 | 2013 | 4244 | 0.130 |
Why?
|
Obesity | 6 | 2020 | 12947 | 0.130 |
Why?
|
Research | 2 | 2018 | 1982 | 0.130 |
Why?
|
Physicians | 1 | 2014 | 4591 | 0.130 |
Why?
|
Tryptophan | 2 | 2012 | 482 | 0.130 |
Why?
|
Body Mass Index | 6 | 2021 | 12953 | 0.130 |
Why?
|
Patient Satisfaction | 3 | 2019 | 3461 | 0.130 |
Why?
|
Mental Health Services | 4 | 2020 | 1730 | 0.130 |
Why?
|
Stereotaxic Techniques | 5 | 2003 | 555 | 0.130 |
Why?
|
Nausea | 1 | 2019 | 679 | 0.130 |
Why?
|
Drug Synergism | 7 | 2016 | 1755 | 0.130 |
Why?
|
Central Nervous System Stimulants | 2 | 2010 | 1177 | 0.130 |
Why?
|
Child | 16 | 2022 | 80153 | 0.130 |
Why?
|
Glutathione | 1 | 2018 | 583 | 0.120 |
Why?
|
C-Reactive Protein | 3 | 2022 | 3826 | 0.120 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 11903 | 0.120 |
Why?
|
Irritable Bowel Syndrome | 1 | 2020 | 455 | 0.120 |
Why?
|
Health Status | 6 | 2010 | 4077 | 0.120 |
Why?
|
Linear Models | 2 | 2016 | 5871 | 0.120 |
Why?
|
Registries | 2 | 2024 | 8224 | 0.120 |
Why?
|
World Health Organization | 1 | 2021 | 1322 | 0.120 |
Why?
|
Cost Sharing | 2 | 2020 | 409 | 0.120 |
Why?
|
Sickness Impact Profile | 3 | 2012 | 299 | 0.120 |
Why?
|
Proportional Hazards Models | 7 | 2018 | 12463 | 0.120 |
Why?
|
Polymorphism, Genetic | 3 | 2012 | 4243 | 0.120 |
Why?
|
Herbal Medicine | 1 | 2014 | 36 | 0.120 |
Why?
|
Yoga | 1 | 2018 | 281 | 0.110 |
Why?
|
Fructose | 1 | 2016 | 288 | 0.110 |
Why?
|
Therapeutic Equivalency | 1 | 2013 | 134 | 0.110 |
Why?
|
National Institute on Alcohol Abuse and Alcoholism (U.S.) | 1 | 2013 | 10 | 0.110 |
Why?
|
Algorithms | 5 | 2016 | 14031 | 0.110 |
Why?
|
Bayes Theorem | 1 | 2021 | 2330 | 0.110 |
Why?
|
Learning | 1 | 2023 | 1740 | 0.110 |
Why?
|
Medicare | 2 | 2023 | 6770 | 0.110 |
Why?
|
Interview, Psychological | 5 | 2013 | 809 | 0.110 |
Why?
|
Lipotropic Agents | 1 | 2012 | 13 | 0.110 |
Why?
|
Program Evaluation | 3 | 2014 | 2495 | 0.110 |
Why?
|
Predictive Value of Tests | 5 | 2017 | 15266 | 0.110 |
Why?
|
Multivariate Analysis | 3 | 2016 | 12059 | 0.110 |
Why?
|
Mental Recall | 2 | 2017 | 1214 | 0.110 |
Why?
|
Akathisia, Drug-Induced | 3 | 2002 | 67 | 0.100 |
Why?
|
Self-Injurious Behavior | 1 | 1999 | 566 | 0.100 |
Why?
|
Aggression | 2 | 2000 | 750 | 0.100 |
Why?
|
Retrospective Studies | 22 | 2022 | 80636 | 0.100 |
Why?
|
Intention to Treat Analysis | 1 | 2013 | 413 | 0.100 |
Why?
|
Family Relations | 1 | 2014 | 317 | 0.100 |
Why?
|
Neural Pathways | 2 | 2022 | 3058 | 0.100 |
Why?
|
Osteoporosis | 1 | 2022 | 1606 | 0.100 |
Why?
|
Genes, Mitochondrial | 1 | 2012 | 59 | 0.100 |
Why?
|
Linoleic Acid | 1 | 2013 | 158 | 0.100 |
Why?
|
Benzothiazoles | 1 | 2013 | 247 | 0.100 |
Why?
|
Chromium | 1 | 2012 | 132 | 0.100 |
Why?
|
Work | 1 | 2013 | 195 | 0.100 |
Why?
|
Liver Diseases | 1 | 2020 | 1298 | 0.100 |
Why?
|
Personality Assessment | 5 | 2015 | 650 | 0.100 |
Why?
|
Body Weight | 4 | 2018 | 4618 | 0.100 |
Why?
|
Adaptation, Psychological | 4 | 2017 | 2629 | 0.100 |
Why?
|
Serotonin Receptor Agonists | 3 | 2008 | 151 | 0.100 |
Why?
|
Psychosurgery | 2 | 2002 | 86 | 0.100 |
Why?
|
Obstetric Labor Complications | 1 | 2014 | 236 | 0.100 |
Why?
|
Magnesium | 2 | 2012 | 804 | 0.100 |
Why?
|
Free Radical Scavengers | 1 | 2012 | 211 | 0.090 |
Why?
|
Nootropic Agents | 1 | 2012 | 157 | 0.090 |
Why?
|
Drug Costs | 3 | 2011 | 1183 | 0.090 |
Why?
|
Health Education | 1 | 2018 | 1052 | 0.090 |
Why?
|
Trace Elements | 1 | 2012 | 195 | 0.090 |
Why?
|
Neoplasms | 5 | 2022 | 22170 | 0.090 |
Why?
|
Telecommunications | 1 | 2011 | 80 | 0.090 |
Why?
|
Socioeconomic Factors | 10 | 2013 | 7827 | 0.090 |
Why?
|
Time Factors | 20 | 2017 | 39967 | 0.090 |
Why?
|
Regression Analysis | 8 | 2018 | 6343 | 0.090 |
Why?
|
Premenstrual Syndrome | 1 | 2011 | 109 | 0.090 |
Why?
|
Hippocampus | 2 | 2017 | 3766 | 0.090 |
Why?
|
Oxidative Phosphorylation | 1 | 2012 | 496 | 0.090 |
Why?
|
Prescriptions | 2 | 2023 | 386 | 0.090 |
Why?
|
Peer Group | 1 | 2015 | 692 | 0.090 |
Why?
|
Efficiency | 1 | 2013 | 476 | 0.090 |
Why?
|
Circadian Rhythm Signaling Peptides and Proteins | 1 | 2009 | 29 | 0.090 |
Why?
|
Magnetic Resonance Spectroscopy | 4 | 2009 | 3769 | 0.090 |
Why?
|
Data Interpretation, Statistical | 4 | 2010 | 2691 | 0.080 |
Why?
|
United States Food and Drug Administration | 2 | 2009 | 1664 | 0.080 |
Why?
|
Antioxidants | 1 | 2018 | 1668 | 0.080 |
Why?
|
History, 17th Century | 1 | 2009 | 108 | 0.080 |
Why?
|
Schizophrenia | 4 | 2020 | 6937 | 0.080 |
Why?
|
Psychology | 2 | 2008 | 356 | 0.080 |
Why?
|
Neuroprotective Agents | 2 | 2016 | 957 | 0.080 |
Why?
|
Caregivers | 3 | 2022 | 2237 | 0.080 |
Why?
|
Limbic System | 2 | 2002 | 419 | 0.080 |
Why?
|
Alcoholism | 5 | 2010 | 1973 | 0.080 |
Why?
|
Nonlinear Dynamics | 1 | 2012 | 492 | 0.080 |
Why?
|
Sports | 1 | 2015 | 705 | 0.080 |
Why?
|
Neuroleptic Malignant Syndrome | 1 | 1989 | 74 | 0.080 |
Why?
|
Serotonin | 2 | 2005 | 1041 | 0.080 |
Why?
|
Thiazoles | 2 | 2008 | 1517 | 0.080 |
Why?
|
Quality Indicators, Health Care | 1 | 2018 | 1792 | 0.080 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2010 | 367 | 0.080 |
Why?
|
Public Health Informatics | 1 | 2009 | 109 | 0.080 |
Why?
|
Acute Disease | 2 | 2010 | 7237 | 0.080 |
Why?
|
Diagnosis, Dual (Psychiatry) | 4 | 2016 | 303 | 0.080 |
Why?
|
Cyclothymic Disorder | 2 | 2006 | 42 | 0.080 |
Why?
|
Colitis, Ulcerative | 1 | 2020 | 1922 | 0.080 |
Why?
|
Pain | 2 | 2017 | 5073 | 0.080 |
Why?
|
Survival Analysis | 6 | 2009 | 10090 | 0.080 |
Why?
|
Arousal | 3 | 2010 | 1166 | 0.080 |
Why?
|
Thyroid Diseases | 1 | 2011 | 386 | 0.080 |
Why?
|
Mental Status Schedule | 1 | 2009 | 314 | 0.080 |
Why?
|
Psychopathology | 2 | 2015 | 432 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 4 | 2015 | 6484 | 0.080 |
Why?
|
Glycolysis | 1 | 2012 | 835 | 0.080 |
Why?
|
Blood Proteins | 1 | 2013 | 1173 | 0.070 |
Why?
|
Statistics, Nonparametric | 6 | 2012 | 2850 | 0.070 |
Why?
|
Cerebral Cortex | 3 | 2018 | 5777 | 0.070 |
Why?
|
Smoking Cessation | 1 | 2019 | 2056 | 0.070 |
Why?
|
Sex Characteristics | 2 | 2016 | 2639 | 0.070 |
Why?
|
Personal Autonomy | 1 | 2010 | 304 | 0.070 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2013 | 1241 | 0.070 |
Why?
|
Retreatment | 3 | 2008 | 598 | 0.070 |
Why?
|
Case-Control Studies | 7 | 2017 | 22176 | 0.070 |
Why?
|
History, 19th Century | 1 | 2009 | 720 | 0.070 |
Why?
|
Industry | 1 | 2009 | 364 | 0.070 |
Why?
|
Agoraphobia | 3 | 2004 | 177 | 0.070 |
Why?
|
Enuresis | 1 | 2006 | 50 | 0.070 |
Why?
|
Odds Ratio | 4 | 2013 | 9646 | 0.070 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2012 | 710 | 0.070 |
Why?
|
1-Naphthylamine | 2 | 1997 | 49 | 0.070 |
Why?
|
Xerostomia | 1 | 2007 | 94 | 0.070 |
Why?
|
Aspartic Acid | 1 | 2009 | 576 | 0.070 |
Why?
|
Decision Support Systems, Clinical | 1 | 2016 | 1175 | 0.070 |
Why?
|
Income | 2 | 2020 | 1877 | 0.070 |
Why?
|
Aged, 80 and over | 9 | 2024 | 58976 | 0.070 |
Why?
|
Mass Screening | 3 | 2012 | 5428 | 0.070 |
Why?
|
Mind-Body Therapies | 1 | 2009 | 279 | 0.070 |
Why?
|
Genetic Testing | 1 | 2019 | 3537 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 5 | 2010 | 17904 | 0.070 |
Why?
|
Patient Care Planning | 2 | 2009 | 908 | 0.070 |
Why?
|
Home Nursing | 1 | 2006 | 92 | 0.060 |
Why?
|
Marketing | 1 | 2008 | 220 | 0.060 |
Why?
|
Peer Review, Research | 1 | 2009 | 340 | 0.060 |
Why?
|
Weight Gain | 2 | 2009 | 2348 | 0.060 |
Why?
|
Fluvoxamine | 2 | 2010 | 78 | 0.060 |
Why?
|
Chromosome Breakage | 1 | 2006 | 159 | 0.060 |
Why?
|
Erectile Dysfunction | 2 | 2007 | 444 | 0.060 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2009 | 793 | 0.060 |
Why?
|
Sensitivity and Specificity | 5 | 2018 | 14666 | 0.060 |
Why?
|
S-Adenosylmethionine | 2 | 2004 | 218 | 0.060 |
Why?
|
Methylphenidate | 1 | 2010 | 488 | 0.060 |
Why?
|
Indans | 1 | 2006 | 92 | 0.060 |
Why?
|
Self Care | 2 | 2022 | 796 | 0.060 |
Why?
|
Basal Ganglia | 2 | 1999 | 554 | 0.060 |
Why?
|
Health Services Needs and Demand | 1 | 2013 | 1403 | 0.060 |
Why?
|
September 11 Terrorist Attacks | 1 | 2006 | 105 | 0.060 |
Why?
|
Lipids | 2 | 2014 | 3341 | 0.060 |
Why?
|
Down-Regulation | 1 | 2012 | 2919 | 0.060 |
Why?
|
Gastrointestinal Diseases | 3 | 2010 | 1200 | 0.060 |
Why?
|
Publication Bias | 1 | 2005 | 160 | 0.060 |
Why?
|
Linkage Disequilibrium | 1 | 2010 | 1998 | 0.060 |
Why?
|
Research Support as Topic | 1 | 2009 | 697 | 0.060 |
Why?
|
Child, Preschool | 6 | 2022 | 42230 | 0.060 |
Why?
|
Hormone Replacement Therapy | 1 | 2010 | 751 | 0.060 |
Why?
|
Periodicity | 1 | 2006 | 348 | 0.060 |
Why?
|
Chi-Square Distribution | 4 | 2005 | 3416 | 0.060 |
Why?
|
Family Therapy | 3 | 2016 | 215 | 0.060 |
Why?
|
Conduct Disorder | 1 | 2006 | 245 | 0.060 |
Why?
|
Metabolic Diseases | 1 | 2011 | 683 | 0.060 |
Why?
|
Behavior, Animal | 1 | 2012 | 1878 | 0.060 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 2006 | 297 | 0.060 |
Why?
|
Fenfluramine | 2 | 2003 | 58 | 0.060 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2008 | 494 | 0.060 |
Why?
|
Safety Management | 1 | 2009 | 760 | 0.060 |
Why?
|
Prolactin | 2 | 2003 | 625 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2015 | 3575 | 0.050 |
Why?
|
Tomography, Emission-Computed | 2 | 2003 | 1122 | 0.050 |
Why?
|
Memory Disorders | 3 | 2005 | 1198 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2022 | 7407 | 0.050 |
Why?
|
Amitriptyline | 1 | 2023 | 112 | 0.050 |
Why?
|
Protons | 1 | 2009 | 1116 | 0.050 |
Why?
|
Culture | 2 | 2004 | 623 | 0.050 |
Why?
|
Telencephalon | 1 | 2003 | 142 | 0.050 |
Why?
|
Hypertension | 4 | 2013 | 8540 | 0.050 |
Why?
|
Grief | 1 | 2005 | 254 | 0.050 |
Why?
|
Up-Regulation | 1 | 2012 | 4124 | 0.050 |
Why?
|
Rest | 2 | 2018 | 918 | 0.050 |
Why?
|
Employment | 4 | 2016 | 1118 | 0.050 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2013 | 1188 | 0.050 |
Why?
|
Specialization | 1 | 2008 | 778 | 0.050 |
Why?
|
Epidemiologic Methods | 2 | 2006 | 1336 | 0.050 |
Why?
|
Ethics, Medical | 1 | 2008 | 783 | 0.050 |
Why?
|
Hypochondriasis | 2 | 2009 | 93 | 0.050 |
Why?
|
Vagus Nerve | 1 | 2005 | 458 | 0.050 |
Why?
|
Reference Values | 6 | 2007 | 4920 | 0.050 |
Why?
|
Students | 1 | 2012 | 1741 | 0.050 |
Why?
|
Caudate Nucleus | 2 | 2000 | 389 | 0.050 |
Why?
|
Folic Acid Deficiency | 2 | 2000 | 117 | 0.050 |
Why?
|
Menopause | 1 | 2010 | 1646 | 0.050 |
Why?
|
Memory, Short-Term | 1 | 2008 | 982 | 0.050 |
Why?
|
Episode of Care | 1 | 2002 | 128 | 0.050 |
Why?
|
Substance Withdrawal Syndrome | 2 | 1997 | 625 | 0.050 |
Why?
|
Insurance Coverage | 1 | 2013 | 1940 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2019 | 18252 | 0.050 |
Why?
|
Self Mutilation | 1 | 2001 | 57 | 0.050 |
Why?
|
Overweight | 1 | 2013 | 2417 | 0.050 |
Why?
|
Likelihood Functions | 3 | 2011 | 992 | 0.050 |
Why?
|
Education | 2 | 2018 | 537 | 0.050 |
Why?
|
China | 2 | 2010 | 2369 | 0.050 |
Why?
|
Postmenopause | 1 | 2010 | 2513 | 0.050 |
Why?
|
Thinking | 2 | 2011 | 320 | 0.050 |
Why?
|
Triglycerides | 2 | 2014 | 2461 | 0.050 |
Why?
|
Patient Compliance | 2 | 2007 | 2690 | 0.050 |
Why?
|
Data Collection | 3 | 2006 | 3322 | 0.050 |
Why?
|
Nervous System Diseases | 1 | 2011 | 1666 | 0.050 |
Why?
|
Cluster Analysis | 3 | 2016 | 2707 | 0.050 |
Why?
|
Anti-Anxiety Agents | 2 | 2018 | 397 | 0.050 |
Why?
|
Faculty, Medical | 1 | 2009 | 1203 | 0.040 |
Why?
|
Dexamethasone | 1 | 1988 | 1948 | 0.040 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2002 | 189 | 0.040 |
Why?
|
Minority Groups | 2 | 2023 | 1203 | 0.040 |
Why?
|
Drug Utilization Review | 1 | 2001 | 248 | 0.040 |
Why?
|
Migraine Disorders | 1 | 2013 | 1701 | 0.040 |
Why?
|
Attention | 4 | 2008 | 2396 | 0.040 |
Why?
|
Leucovorin | 1 | 2002 | 643 | 0.040 |
Why?
|
Carbamazepine | 1 | 2020 | 224 | 0.040 |
Why?
|
Epidemiologic Research Design | 1 | 2003 | 368 | 0.040 |
Why?
|
Telomere | 1 | 2006 | 943 | 0.040 |
Why?
|
Injections, Intramuscular | 2 | 2012 | 554 | 0.040 |
Why?
|
Australia | 1 | 2023 | 1250 | 0.040 |
Why?
|
Hypercholesterolemia | 2 | 2005 | 1141 | 0.040 |
Why?
|
Medicine | 1 | 2008 | 942 | 0.040 |
Why?
|
Self-Assessment | 1 | 2002 | 396 | 0.040 |
Why?
|
Benzophenones | 1 | 1999 | 58 | 0.040 |
Why?
|
Hydrocortisone | 2 | 2003 | 1819 | 0.040 |
Why?
|
Electric Stimulation Therapy | 1 | 2005 | 628 | 0.040 |
Why?
|
Clomipramine | 1 | 1999 | 54 | 0.040 |
Why?
|
Interleukin-6 | 2 | 2022 | 3208 | 0.040 |
Why?
|
Jurisprudence | 1 | 1999 | 109 | 0.040 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2002 | 357 | 0.040 |
Why?
|
Emigration and Immigration | 1 | 2002 | 397 | 0.040 |
Why?
|
Insurance Benefits | 1 | 2020 | 187 | 0.040 |
Why?
|
Critical Pathways | 1 | 2002 | 474 | 0.040 |
Why?
|
Health Benefit Plans, Employee | 1 | 2001 | 333 | 0.040 |
Why?
|
Drug Utilization | 2 | 2020 | 1188 | 0.040 |
Why?
|
Dominance, Cerebral | 3 | 2008 | 623 | 0.040 |
Why?
|
Cross-Cultural Comparison | 1 | 2002 | 635 | 0.040 |
Why?
|
Nutritional Physiological Phenomena | 1 | 2000 | 363 | 0.040 |
Why?
|
Factor Analysis, Statistical | 2 | 2011 | 999 | 0.040 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2008 | 1228 | 0.040 |
Why?
|
Pemoline | 1 | 1998 | 18 | 0.040 |
Why?
|
Sexual and Gender Disorders | 1 | 1998 | 6 | 0.040 |
Why?
|
Self Medication | 1 | 1998 | 117 | 0.040 |
Why?
|
Confidence Intervals | 2 | 2013 | 2927 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2009 | 5789 | 0.040 |
Why?
|
ROC Curve | 1 | 2006 | 3579 | 0.040 |
Why?
|
Inflammation | 3 | 2022 | 10773 | 0.040 |
Why?
|
Republic of Korea | 1 | 2020 | 590 | 0.040 |
Why?
|
Creatinine | 1 | 2023 | 1899 | 0.040 |
Why?
|
Asthma | 2 | 2014 | 6234 | 0.040 |
Why?
|
Attitude of Health Personnel | 1 | 1991 | 3889 | 0.040 |
Why?
|
Creatine | 1 | 1999 | 427 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2009 | 2751 | 0.040 |
Why?
|
Piperidines | 1 | 2006 | 1656 | 0.040 |
Why?
|
Proton Pump Inhibitors | 1 | 2022 | 532 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2007 | 2244 | 0.030 |
Why?
|
Life Change Events | 2 | 2006 | 952 | 0.030 |
Why?
|
Social Behavior Disorders | 1 | 1997 | 96 | 0.030 |
Why?
|
Educational Status | 3 | 2010 | 2522 | 0.030 |
Why?
|
Energy Metabolism | 1 | 2008 | 2882 | 0.030 |
Why?
|
Decision Trees | 3 | 2007 | 504 | 0.030 |
Why?
|
Sex | 1 | 1996 | 53 | 0.030 |
Why?
|
Thyroid Gland | 1 | 2023 | 1168 | 0.030 |
Why?
|
Cytosol | 1 | 1999 | 888 | 0.030 |
Why?
|
Brief Psychiatric Rating Scale | 2 | 2006 | 109 | 0.030 |
Why?
|
Health Care Surveys | 2 | 2020 | 2426 | 0.030 |
Why?
|
Personality Development | 1 | 1996 | 244 | 0.030 |
Why?
|
Receptors, Immunologic | 1 | 2022 | 1410 | 0.030 |
Why?
|
Expressed Emotion | 1 | 1996 | 92 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 1844 | 0.030 |
Why?
|
Drug Prescriptions | 2 | 2002 | 1670 | 0.030 |
Why?
|
Interviews as Topic | 3 | 2008 | 2696 | 0.030 |
Why?
|
Circadian Rhythm | 2 | 2021 | 2576 | 0.030 |
Why?
|
Workplace | 1 | 2001 | 863 | 0.030 |
Why?
|
Boston | 3 | 2003 | 9326 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2021 | 846 | 0.030 |
Why?
|
Melissa | 1 | 2014 | 1 | 0.030 |
Why?
|
Chamomile | 1 | 2014 | 2 | 0.030 |
Why?
|
Passiflora | 1 | 2014 | 4 | 0.030 |
Why?
|
Valerian | 1 | 2014 | 4 | 0.030 |
Why?
|
Waist Circumference | 1 | 2018 | 935 | 0.030 |
Why?
|
Evaluation Studies as Topic | 2 | 2005 | 1624 | 0.030 |
Why?
|
Family | 1 | 2005 | 3194 | 0.030 |
Why?
|
Radioimmunoassay | 2 | 2001 | 862 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2004 | 2180 | 0.030 |
Why?
|
Surgery, Computer-Assisted | 1 | 2002 | 1007 | 0.030 |
Why?
|
Brain Chemistry | 1 | 2018 | 960 | 0.030 |
Why?
|
Weight Loss | 2 | 2019 | 2684 | 0.030 |
Why?
|
Amygdala | 2 | 2018 | 1354 | 0.030 |
Why?
|
Bulimia | 3 | 1996 | 400 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2008 | 9000 | 0.030 |
Why?
|
Models, Statistical | 2 | 2006 | 5079 | 0.030 |
Why?
|
Clinical Competence | 1 | 2009 | 4792 | 0.030 |
Why?
|
Fatigue | 3 | 2008 | 1552 | 0.030 |
Why?
|
Program Development | 1 | 2020 | 1297 | 0.030 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2015 | 299 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2010 | 15936 | 0.030 |
Why?
|
Drug Resistance, Bacterial | 1 | 2020 | 1048 | 0.030 |
Why?
|
Emergency Services, Psychiatric | 1 | 2013 | 67 | 0.030 |
Why?
|
Mutation | 1 | 2017 | 30052 | 0.030 |
Why?
|
Health Care Costs | 1 | 2006 | 3242 | 0.030 |
Why?
|
Pulse | 2 | 1991 | 217 | 0.030 |
Why?
|
Gene Frequency | 2 | 2009 | 3606 | 0.030 |
Why?
|
Visual Perception | 1 | 2001 | 1387 | 0.030 |
Why?
|
Cytokines | 1 | 2007 | 7396 | 0.030 |
Why?
|
Hospitalization | 3 | 2020 | 10723 | 0.020 |
Why?
|
Caffeine | 1 | 1996 | 700 | 0.020 |
Why?
|
Propiophenones | 1 | 1991 | 28 | 0.020 |
Why?
|
Child Abuse | 1 | 2020 | 1077 | 0.020 |
Why?
|
Nicotine | 1 | 1996 | 680 | 0.020 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 1992 | 165 | 0.020 |
Why?
|
Methoxyhydroxyphenylglycol | 1 | 1991 | 93 | 0.020 |
Why?
|
Rats, Inbred F344 | 1 | 2012 | 826 | 0.020 |
Why?
|
Semantics | 2 | 2005 | 601 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2009 | 5336 | 0.020 |
Why?
|
Pituitary-Adrenal System | 1 | 2014 | 552 | 0.020 |
Why?
|
Propensity Score | 1 | 2018 | 1913 | 0.020 |
Why?
|
Quality of Health Care | 2 | 2018 | 4330 | 0.020 |
Why?
|
DNA | 1 | 2005 | 7212 | 0.020 |
Why?
|
Thyroxine | 1 | 2014 | 666 | 0.020 |
Why?
|
Dopamine Agonists | 1 | 2013 | 352 | 0.020 |
Why?
|
Phenylalanine | 1 | 1992 | 366 | 0.020 |
Why?
|
Cross-Over Studies | 2 | 2007 | 2078 | 0.020 |
Why?
|
Neurosurgical Procedures | 1 | 2001 | 2072 | 0.020 |
Why?
|
Medicare Part C | 1 | 2016 | 334 | 0.020 |
Why?
|
Ethanol | 1 | 1996 | 1324 | 0.020 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2014 | 701 | 0.020 |
Why?
|
Calcium | 1 | 2023 | 5722 | 0.020 |
Why?
|
Blood Pressure | 3 | 1991 | 8481 | 0.020 |
Why?
|
Delphi Technique | 1 | 2013 | 846 | 0.020 |
Why?
|
Group Processes | 1 | 2011 | 228 | 0.020 |
Why?
|
Guideline Adherence | 2 | 2010 | 2220 | 0.020 |
Why?
|
Advisory Committees | 1 | 2013 | 787 | 0.020 |
Why?
|
Euphoria | 1 | 2009 | 65 | 0.020 |
Why?
|
Patient Admission | 1 | 2016 | 1367 | 0.020 |
Why?
|
Empathy | 1 | 2013 | 473 | 0.020 |
Why?
|
Norepinephrine | 1 | 1991 | 897 | 0.020 |
Why?
|
Age Distribution | 2 | 2007 | 2880 | 0.020 |
Why?
|
Marriage | 1 | 2010 | 351 | 0.020 |
Why?
|
Single Person | 1 | 2007 | 31 | 0.020 |
Why?
|
Task Performance and Analysis | 1 | 2011 | 763 | 0.020 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2008 | 353 | 0.020 |
Why?
|
Awareness | 1 | 2011 | 648 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2014 | 1814 | 0.020 |
Why?
|
Phosphocreatine | 1 | 2008 | 261 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 1998 | 3712 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3358 | 0.020 |
Why?
|
Aging | 1 | 2006 | 8708 | 0.020 |
Why?
|
Software | 1 | 2021 | 4434 | 0.020 |
Why?
|
Leptin | 1 | 2015 | 1597 | 0.020 |
Why?
|
Physical Fitness | 1 | 2011 | 743 | 0.020 |
Why?
|
Heart Block | 1 | 2008 | 386 | 0.020 |
Why?
|
Quality Assurance, Health Care | 2 | 2009 | 2169 | 0.020 |
Why?
|
Borderline Personality Disorder | 1 | 1994 | 768 | 0.020 |
Why?
|
Alcohol Drinking | 2 | 2016 | 4028 | 0.020 |
Why?
|
Defense Mechanisms | 1 | 2006 | 180 | 0.020 |
Why?
|
Health Status Indicators | 1 | 2011 | 970 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2020 | 4486 | 0.020 |
Why?
|
Matched-Pair Analysis | 1 | 2006 | 284 | 0.020 |
Why?
|
Population Surveillance | 1 | 2016 | 2598 | 0.020 |
Why?
|
False Positive Reactions | 1 | 1988 | 957 | 0.020 |
Why?
|
Marital Therapy | 1 | 2005 | 44 | 0.020 |
Why?
|
Speech Recognition Software | 1 | 2005 | 74 | 0.020 |
Why?
|
Academic Medical Centers | 2 | 2006 | 2759 | 0.020 |
Why?
|
Genotype | 2 | 2009 | 12990 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 1998 | 2947 | 0.010 |
Why?
|
Wechsler Scales | 1 | 2005 | 257 | 0.010 |
Why?
|
Postoperative Complications | 3 | 2002 | 15631 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2014 | 2382 | 0.010 |
Why?
|
Cerebral Ventricles | 1 | 2007 | 542 | 0.010 |
Why?
|
Serotonin 5-HT1 Receptor Agonists | 1 | 2004 | 42 | 0.010 |
Why?
|
Self Concept | 1 | 2010 | 1045 | 0.010 |
Why?
|
Blood Platelets | 1 | 2014 | 2479 | 0.010 |
Why?
|
Massachusetts | 3 | 2002 | 8830 | 0.010 |
Why?
|
Models, Psychological | 1 | 2007 | 828 | 0.010 |
Why?
|
Social Environment | 1 | 2008 | 1020 | 0.010 |
Why?
|
Chemokines | 1 | 2007 | 960 | 0.010 |
Why?
|
Mass Media | 1 | 2006 | 303 | 0.010 |
Why?
|
Endpoint Determination | 1 | 2005 | 590 | 0.010 |
Why?
|
Databases, Genetic | 1 | 2009 | 1742 | 0.010 |
Why?
|
Nova Scotia | 1 | 2002 | 34 | 0.010 |
Why?
|
Juvenile Delinquency | 1 | 2003 | 117 | 0.010 |
Why?
|
Time | 1 | 2004 | 546 | 0.010 |
Why?
|
Orgasm | 1 | 2002 | 61 | 0.010 |
Why?
|
Reaction Time | 1 | 2008 | 2082 | 0.010 |
Why?
|
Stereotyping | 1 | 2004 | 239 | 0.010 |
Why?
|
Databases, Factual | 1 | 2017 | 7967 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8654 | 0.010 |
Why?
|
Libido | 1 | 2002 | 119 | 0.010 |
Why?
|
Pregnancy | 3 | 2014 | 29874 | 0.010 |
Why?
|
Adenosine Triphosphate | 1 | 2008 | 1989 | 0.010 |
Why?
|
Parents | 1 | 2015 | 3563 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2010 | 4615 | 0.010 |
Why?
|
Achievement | 1 | 2003 | 288 | 0.010 |
Why?
|
Seizures | 1 | 2014 | 2957 | 0.010 |
Why?
|
Amino Acids | 2 | 2001 | 1718 | 0.010 |
Why?
|
Health Expenditures | 1 | 2013 | 2366 | 0.010 |
Why?
|
Sample Size | 1 | 2004 | 841 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2006 | 1668 | 0.010 |
Why?
|
Sampling Studies | 1 | 2002 | 615 | 0.010 |
Why?
|
Animals | 3 | 2019 | 168459 | 0.010 |
Why?
|
Fatty Acids | 1 | 2008 | 1808 | 0.010 |
Why?
|
Observer Variation | 1 | 2006 | 2606 | 0.010 |
Why?
|
Cerebrovascular Disorders | 1 | 2007 | 1474 | 0.010 |
Why?
|
Cues | 1 | 2005 | 875 | 0.010 |
Why?
|
Phenotype | 2 | 2010 | 16591 | 0.010 |
Why?
|
Artificial Intelligence | 1 | 2014 | 2578 | 0.010 |
Why?
|
California | 1 | 2004 | 1429 | 0.010 |
Why?
|
Heart Rate | 1 | 1991 | 4195 | 0.010 |
Why?
|
Mental Processes | 1 | 2001 | 244 | 0.010 |
Why?
|
Nitrophenols | 1 | 1999 | 169 | 0.010 |
Why?
|
Health Promotion | 1 | 2011 | 2214 | 0.010 |
Why?
|
Economics, Pharmaceutical | 1 | 1999 | 87 | 0.010 |
Why?
|
Psychopharmacology | 1 | 2000 | 148 | 0.010 |
Why?
|
Pain Measurement | 1 | 2008 | 3550 | 0.010 |
Why?
|
Behavior | 1 | 2001 | 541 | 0.010 |
Why?
|
Hospitals, General | 1 | 2002 | 798 | 0.010 |
Why?
|
Texas | 1 | 1999 | 404 | 0.010 |
Why?
|
Urinary Incontinence | 1 | 2002 | 489 | 0.010 |
Why?
|
Insurance, Health | 1 | 2010 | 2498 | 0.010 |
Why?
|
Temperament | 1 | 2000 | 297 | 0.010 |
Why?
|
Professional Competence | 1 | 2000 | 431 | 0.010 |
Why?
|
Histrionic Personality Disorder | 1 | 1996 | 10 | 0.010 |
Why?
|
Postoperative Period | 1 | 2001 | 1813 | 0.010 |
Why?
|
Canada | 1 | 2002 | 2122 | 0.010 |
Why?
|
Rats | 1 | 2012 | 23742 | 0.010 |
Why?
|
Vitamin B 12 Deficiency | 1 | 1997 | 118 | 0.010 |
Why?
|
Models, Genetic | 1 | 2006 | 3442 | 0.010 |
Why?
|
Community Mental Health Services | 1 | 1999 | 392 | 0.010 |
Why?
|
Health Services Research | 1 | 2003 | 1812 | 0.010 |
Why?
|
Pregnancy Outcome | 1 | 2006 | 2921 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2013 | 5440 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2004 | 2421 | 0.010 |
Why?
|
Sulfones | 1 | 1998 | 448 | 0.010 |
Why?
|
Purines | 1 | 1998 | 607 | 0.010 |
Why?
|
Marital Status | 1 | 1996 | 426 | 0.010 |
Why?
|
Thalamus | 1 | 2000 | 1045 | 0.010 |
Why?
|
Propranolol | 1 | 1996 | 489 | 0.010 |
Why?
|
Vertigo | 1 | 1995 | 202 | 0.010 |
Why?
|
Incidence | 2 | 2002 | 21353 | 0.010 |
Why?
|
Tinnitus | 1 | 1995 | 196 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2001 | 2010 | 0.010 |
Why?
|
Frontal Lobe | 1 | 1999 | 1420 | 0.010 |
Why?
|
Neurologic Examination | 1 | 1996 | 916 | 0.010 |
Why?
|
Preoperative Care | 1 | 2001 | 2242 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2001 | 2651 | 0.010 |
Why?
|
Amphetamines | 1 | 1991 | 143 | 0.010 |
Why?
|
Gait | 1 | 1995 | 814 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2009 | 12690 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2003 | 5492 | 0.010 |
Why?
|
Pargyline | 1 | 1989 | 19 | 0.010 |
Why?
|
Phenelzine | 1 | 1989 | 28 | 0.010 |
Why?
|
Administration, Oral | 1 | 1998 | 4021 | 0.010 |
Why?
|
Panic | 1 | 1989 | 103 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2005 | 6485 | 0.010 |
Why?
|
Headache | 1 | 1995 | 1256 | 0.000 |
Why?
|
Posture | 1 | 1991 | 957 | 0.000 |
Why?
|
Reoperation | 1 | 1996 | 4303 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2008 | 20570 | 0.000 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 1997 | 3357 | 0.000 |
Why?
|
Diet | 1 | 2001 | 8075 | 0.000 |
Why?
|